Behavioral phenotyping of minipigs transgenic for the Huntington gene

Journal of Neuroscience Methods

Volumn 265, Issue , 2016, Pages 34-45

  Schramke, Sarah ^a,b   Schuldenzucker, Verena ^a   Schubert, Robin ^a   Frank, Frauke ^a,c   Wirsig, Maike ^a   Ott, Stefanie ^a   Motlik, Jan ^c   Fels, Michaela ^b   Kemper, Nicole ^b   Hölzner, Eva ^a   Reilmann, Ralf ^a,d,e,f  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e Dept of Neurology Muenster ^*  (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Animal models; Behavioral; Cognitive; Minipig; Motor; Phenotyping; Preclinical research

Indexed keywords

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COLOR DISCRIMINATION; COLOR DISCRIMINATION TEST; CONTROLLED STUDY; DOMINANCE BEHAVIOR; DOMINANCE TEST; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; EXPLORATORY BEHAVIOR; FEASIBILITY STUDY; FEMALE; GAIT; GAIT TEST; HUNTINGTON CHOREA; HURDLE TEST; LEARNING; MINIPIG; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; STARTBOX BACK AND FORTH TEST; TONGUE COORDINATION TEST; TRANSGENIC PIG; WILD TYPE; ANIMAL; COLOR VISION; DISEASE MODEL; EQUIPMENT DESIGN; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PERCEPTIVE DISCRIMINATION; PHENOTYPE; PHYSIOLOGY; PIG; PSYCHOLOGY; TONGUE; TRANSGENIC ANIMAL;

HTT PROTEIN, HUMAN; HUNTINGTIN;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BEHAVIOR, ANIMAL; COLOR VISION; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FEMALE; GAIT; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; LEARNING; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; SWINE; SWINE, MINIATURE; TONGUE;

EID: 84954271904     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2015.11.013     Document Type: Article

References (53)

1. Aylward E.H., Harrington D.L., Mills J.A., Nopoulos P.C., Ross C.A., Long J.D., et al. Regional atrophy associated with cognitive and motor function in prodromal huntington disease. J Huntingt Dis 2013, 2:477-489.
2. Baxa M., Hruska-Plochan M., Juhas S., Vodicka P., Pavlok A., Juhasova J., et al. A transgenic minipig model of Huntington's disease. J Huntingt. Dis 2013, 2:47-68.
3. Bechtel N., Scahill R.I., Rosas H.D., Acharya T., van den Bogaard S.J., Jauffret C., et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010, 75:2150-2160.
4. Bohlen S., Ekwall C., Hellstrom K., Vesterlin H., Bjornefur M., Wiklund L., et al. Physical therapy in Huntington's disease-toward objective assessments?. Eur J Neurol 2012, 10-1331.
5. Bonner-Jackson A., Long J.D., Westervelt H., Tremont G., Aylward E., Paulsen J.S. Cognitive reserve and brain reserve in prodromal Huntington's disease. J Int Neuropsychol Soc 2013, 19:739-750.
6. Chang R., Liu X., Li S., Li X.J. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy. Drug Des Dev Ther 2015, 9:2179-2188. (eCollection;%2015.: 2179-88). 10.2147/DDDT.S58470.
7. Craufurd D., Thompson J.C., Snowden J.S. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:219-226.
8. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
9. Dolezalova D., Hruska-Plochan M., Bjarkam C.R., Sorensen J.C., Cunningham M., Weingarten D., et al. Pig models of neurodegenerative disorders: utilization in cell replacement-based preclinical safety and efficacy studies. J Comp Neurol 2014, 522:2784-2801.
10. Dumas E.M., van den Bogaard S.J., Middelkoop H.A., Roos R.A. A review of cognition in Huntington's disease. Front Biosci (Schol Ed) 2013, 5:1-18. (1-18).
11. Epping E.A., Mills J.A., Beglinger L.J., Fiedorowicz J.G., Craufurd D., Smith M.M., et al. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J Psychiatr Res 2013, 47:1423-1431.
12. Fisher C.A., Sewell K., Brown A., Churchyard A. Aggression in Huntington's disease: a systematic review of rates of aggression and treatment methods. J Huntingt Dis 2014, 3:319-332.
13. Grimbergen Y.A., Knol M.J., Bloem B.R., Kremer B.P., Roos R.A., Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord 2008, 23:970-976.
14. Heemskerk A.W., Roos R.A. Dysphagia in Huntingtons disease: a review. Dysphagia 2011, 26:62-66.
15. Howland D.S., Munoz-Sanjuan I. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease. Mov Disord 2014, 29:1397-1403.
16. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996, 11:136-142. Huntington Study Group.
17. Kim J., Bordiuk O.L., Ferrante R.J. Experimental models of HD and reflection on therapeutic strategies. Int Rev Neurobiol 2011, 98:419-481.
18. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 1999, 19:10428-10437.
19. Menalled L., Brunner D. Animal models of Huntington's disease for translation to the clinic: best practices. Mov Disord 2014, 29:1375-1390.
20. Morton A.J., Howland D.S. Large genetic animal models of Huntington's disease. J Huntingt. Dis 2013, 2:3-19.
21. Munoz-Sanjuan I., Bates G.P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 2011, 121:476-483.
22. Paulsen J.S. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011, 11:474-483.
23. Paulsen J.S., Long J.D. Onset of Huntington's disease: can it be purely cognitive?. Mov Disord 2014, 29:1342-1350.
24. Paulsen J.S., Long J.D., Johnson H.J., Aylward E.H., Ross C.A., Williams J.K., et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 2014, 6:78. (eCollection;%2014.:78). 10.3389/fnagi.2014.00078.
25. Philips T., Rothstein J.D., Pouladi M.A. Preclinical models: needed in translation? A Pro/Con debate. Mov Disord 2014, 29:1391-1396.
26. Pouladi M.A., Morton A.J., Hayden M.R. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 2013, 14:708-721.
27. Rao A.K., Muratori L., Louis E.D., Moskowitz C.B., Marder K.S. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 2008, 23:1100-1107.
28. Rao A.K., Mazzoni P., Wasserman P., Marder K. Longitudinal change in gait and motor function in pre-manifest Huntington's disease. PLoS Curr 2011, 3. (RRN1268.: RRN1268).
29. Reilmann R. Huntington's disease: towards disease modification-gaps and bridges, facts and opinions. Basal Ganglia 2012, 2:241-248.
30. Reilmann R., Bohlen S., Klopstock T., Bender A., Weindl A., Saemann P., et al. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Mov Disord 2010, 25:2195-2202.
31. Reilmann R., Leavitt B.R., Ross C.A. Diagnostic criteria for Huntington's disease based on natural history. Mov Disord 2014, 29:1335-1341.
32. Reilmann R, Roos RA, Rosser A, Grimbergen YA, Kraus P, Craufurd D, Dose M, Weindl A, Howard E, Ecker D, Bohlen S, Burgunder JM, Lange HW, Landwehrmeyer GB. A teaching film, video library and online certification for the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS). 2009; 116-117.
33. Reilmann R., Rouzade-Dominguez M.L., Saft C., Suessmuth S., Priller J., Rosser A., et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord 2015, (in press).
34. Reilmann R., Rumpf S., Beckmann H., Koch R., Ringelstein E.B., Lange H.W. Huntington's disease: objective assessment of posture-a link between motor and functional deficits. Mov Disord 2012, 27:555-559.
35. Ross C.A., Aylward E.H., Wild E.J., Langbehn D.R., Long J.D., Warner J.H., et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014, 10:204-216.
36. Ross C.A., Pantelyat A., Kogan J., Brandt J. Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction. Mov Disord 2014, 29:1351-1358.
37. Sampaio C., Borowsky B., Reilmann R. Clinical trials in Huntington's disease: interventions in early clinical development and newer methodological approaches. Mov Disord 2014, 29:1419-1428.
38. Scahill R.I., Hobbs N.Z., Say M.J., Bechtel N., Henley S.M., Hyare H., et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2013, 34:519-529.
39. Schramke S., Schubert R., Frank F., Wirsig M., Fels M., Kemper N., et al. The Libechov minipig as a large animal model for preclinical resarch in Huntington's disease-thoughts and perspectives. Cesk Slov Neurol 2015, 78/111(Suppl 2):55-60.
40. Skodda S., Schlegel U., Hoffmann R., Saft C. Impaired motor speech performance in Huntington's disease. J Neural Transm 2014, 121:399-407.
41. Stout J.C., Jones R., Labuschagne I., O'Regan A.M., Say M.J., Dumas E.M., et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 2012, 83:687-694.
42. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009, 8:791-801.
43. Tabrizi S.J., Reilmann R., Roos R.A., Durr A., Leavitt B., Owen G., et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012, 11:42-53.
44. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011, 10:31-42.
45. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013, 12:637-649.
46. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group, (see comments).
47. Venuto C.S., McGarry A., Ma Q., Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012, 27:31-41.
48. Vodicka P., Smetana K., Dvorankova B., Emerick T., Xu Y.Z., Ourednik J., et al. The miniature pig as an animal model in biomedical research. Ann NY Acad Sci 2005, 1049:161-171.
49. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228. (%20).
50. Weiss J., Becker K., Bernsmann E. Tierpflege in Forschung und Klinik 2008, Enke.
51. Wild E.J., Tabrizi S.J. Targets for future clinical trials in Huntington's disease: what's in the pipeline?. Mov Disord 2014, 29:1434-1445.
52. William Y., Gray X.M. Mouse models for validating preclinical candidates for Huntington's disease. Neurobiology of Huntington's disease: applications to drug discovery 2011, CRC Press, Boca Raton. D.C. Lo, R.E. Hughes (Eds.).
53. Yang S.H., Chan A.W. Transgenic animal models of Huntington's disease. Curr Top Behav Neurosci 2011, 7:61-85.